Basilea's novel oncology drug candidate BAL101553: data

Basilea's novel oncology drug candidate BAL101553: data presented at
international conference demonstrate dual mode of action 
BASEL, SWITZERLAND -- (Marketwire) -- 11/06/12 --  Basilea
Pharmaceutica AG / Basilea's novel oncology drug candidate BAL101553:
data presented at international conference demonstrate dual mode of
action. Processed and transmitted by Thomson Reuters ONE. The issuer
is solely responsible for the content of this announcement. 
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new
research data on its innovative anti-cancer drug BAL101553 are being
presented at the 24(th) Symposium on "Molecular Targets and
Therapeutics" taking place in Dublin, Ireland, from November 6 to 9,
2012, hosted by the European Organisation for Research and Treatment
of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the
American Association for Cancer Research (AACR). 
BAL101553, a highly soluble prodrug of Basilea's BAL27862, is a novel
small molecule agent targeting microtubules, the intracellular
structural network essential for cell division. BAL27862 has
demonstrated broad anti-cancer activity in preclinical models of
human cancer resistant to conventional microtubule-targeting drugs
such as taxanes or vinca alkaloids. BAL101553 has
potential for both
intravenous and oral administration. The injectable form is
being tested in a phase I study in patients with advanced solid
BAL101553 has a dual mechanism of action (poster/abstract #421) with
direct activity against drug-resistant cancer cells and a pronounced
effect on eliminating tumor blood supply. In animal models,
short-term treatment of tumors
led to a dramatic reduction in tumor
cell growth and viability, associated with
almost complete
eradication of functional tumor blood vessels. Importantly, blood
vessel function in normal tissue was not affected. Vascular
activity was also shown in an in vitro model that mimics
capillary formation. 
Further data supporting the unique anti-cancer profile and mode of
action of
this novel agent were generated in collaboration with the
group of Diane Braguer
of the Aix-Marseille University, France.
Details of distinct effects on microtubule biology are presented
(poster/abstract #422). These show that 
BAL27862 blocks tumor cell
division by altering microtubule dynamics in a unique
way as compared
to conventional microtubule-targeting agents. 
Dr. Laurenz Kellenberger, Basilea's Chief Scientific Officer,
commented: "Resistance against established drugs is a major challenge
in cancer therapy and necessitates the development of new oncology
drugs with novel mechanisms of action to overcome such resistance.
The dual mode of action of BAL101553, attacking tumor cells that are
resistant to other agents as well as disrupting
blood vessels of the
tumor underlines its promising profile as a potential new
agent for
the treatment of refractory human cancers." 

|Posters on BAL101553/BAL27862                                 |
|to be presented in poster session "Tubulin-Interacting Agents"|
|on November 8, 2012                                           |
|                                                              |
|Dual mechanism of action of the novel microtubule-targeting   |
|drug BAL27862 (active moiety of the prodrug BAL101553):       |
|targeting tumor and vascular cells - F. Bachmann, H.A. Lane;  |
|poster #421                                                   |
|                                                              |
|Antitumor activity of BAL27862 (active moiety of the prodrug  |
|BAL101553) is associated with the generation of short         |
|non-centrosomal microtubules - A. Rovini, S. Honore, N.       |
|McKay, F. Bachmann, H.A. Lane, D. Braguer; poster #422        |

For further information please visit 
About Basilea 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland,
and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully
integrated research and
development operations of its Swiss
subsidiary Basilea Pharmaceutica International Ltd. ("Basilea") the
company focuses on innovative pharmaceutical
products in the
therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
to current treatment options. 
This communication expressly or implicitly contains certain
statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance
or achievements of Basilea
Pharmaceutica Ltd. to be materially different from
any future
results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a result
of new information, future
events or otherwise. 
This press release can be downloaded from 
Press release (PDF): 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE 
For further information, please contact: 
Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations & Corporate Communications
+41 61 606 1102 
Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Press spacebar to pause and continue. Press esc to stop.